2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. Interleukin Related Isoform

Interleukin Related

 

Interleukin Related Related Products (456):

Cat. No. Product Name Effect Purity
  • HY-102022
    α-Galactosylceramide
    		Inducer
    α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor).
  • HY-P9950
    Omalizumab
    		Inhibitor 99.70%
    Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.
  • HY-P99366A
    Tezepelumab (anti-TSLP)
    		98.64%
    Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma.
  • HY-132832
    Sirpiglenastat
    		99.13%
    Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
  • HY-108810
    Canakinumab
    		Inhibitor 99.64%
    Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.
  • HY-W127433
    Isostearic acid
    		99.08%
    Isostearic acid is a unique fatty acid. Isostearic acid promotes IL-1 release and Apoptosis. Isostearic acid has potent inflammatory properties. Isostearic acid can be used in pharmaceutical, personal care, and cosmetic applications.
  • HY-W1000105
    Geranial
    		Inhibitor 99.51%
    Geranial ((E)-3,7-Dimethylocta-2,6-dienal) is a derivative of geraniol with anti-inflammatory activity. Geranial can inhibit the secretion of TNF-α and IL-6 in macrophages. Furthermore, Geranial also inhibits the secretion of IL-1β mediated by the NLRP-3 inflammasome.
  • HY-P990911
    Crebankitug
    		Inhibitor
    HY-P990911 is an IL7R-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096).
  • HY-P99162
    Nemolizumab
    		Inhibitor 99.70%
    Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD).
  • HY-P9956
    Siltuximab
    		≥99.0%
    Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
  • HY-N0405
    Orientin
    		Inhibitor 99.73%
    Orientin is a neuroprotective agentinhibits which has anti-inflammation, anti-oxidative, anti-tumor, and cardio protection properties. Orientin inhibits the levels of IL-6, IL-1β and TNF-α. Orientin increases IL-10 level. Orientin exhibits neuroprotective effect by inhibits TLR4 and NF-kappa B signaling pathway. Orientin can used in study neuropathic pain.
  • HY-N1178
    Taraxasterol
    		99.41%
    Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases.
  • HY-P9925
    Brodalumab
    		Inhibitor 99.18%
    Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis.
  • HY-P99550
    Tozorakimab
    		Inhibitor 98.82%
    Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease.
  • HY-P99519
    Vixarelimab
    		Inhibitor
    Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.
  • HY-139092
    IL-4-inhibitor-1
    		Inhibitor 98.14%
    IL-4-inhibitor-1 (compound 52) is an IL-4 inhibitor, with an EC50 of 1.81 µM.
  • HY-B0328
    Triamcinolone
    		Inhibitor 99.86%
    Triamcinolone is a long-acting corticosteroid with anti-inflammatory, anti-oedematous, anti-proliferative, anti-angiogenetic, immunomodulatory and neuroprotective effects through binding to glucocorticoid receptors. Triamcinolone can relieve several dermatitis, immune diseases and ocular diseases.
  • HY-P99171
    Gevokizumab
    		Modulator 98.12%
    Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II).
  • HY-P99339
    Tebentafusp
    		99.90%
    Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.
  • HY-W145667
    Mannan
    		Activator 98.10%
    Mannan is an orally active polysaccharide compound that binds to the mannose receptor (MR). Mannan promotes bacterial uptake and endosomal degradation by binding to MR, thereby enhancing the production of IL-12 in immune cells. Mannan enhances ROS production. Mannan modulates immunity, inhibits Aflatoxin B1 (HY-N6615)-induced toxicity, and reduces lipid.